Straits Times Index
3,426.47 -3.98 (-0.12%) Nikkei
37,667.41 -202.10 (-0.53%) Hang Seng
17,021.31 +16.34 (+0.10%) FTSE 100
8,285.71 +99.36 (+1.21%) Bitcoin USD
67,931.11 +2,220.55 (+3.38%) CMC Crypto 200
1,375.16 +44.56 (+3.35%)
Eupraxia Pharmaceuticals Inc. (EPRX.TO)
| Previous close | 3.5000 |
| Open | 3.5400 |
| Bid | 3.5400 x N/A |
| Ask | 3.6200 x N/A |
| Day's range | 3.5400 - 3.7000 |
| 52-week range | 3.2500 - 8.4600 |
| Volume | |
| Avg. volume | 16,480 |
| Market cap | 131.804M |
| Beta (5Y monthly) | 1.18 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
- PR Newswire
Eupraxia Pharmaceuticals to Present at Controlled Release Society 2024 Annual Meeting and Expo
Eupraxia Pharmaceuticals Inc. ("Eupraxia" or the "Company") (TSX: EPRX) (NASDAQ: EPRX), a clinical-stage biotechnology company leveraging its proprietary DiffuSphere™ technology to optimize drug delivery for applications with significant unmet need, today announced that the Company's Chief Operating and Scientific Officer, Dr. Amanda Malone, will be presenting at the upcoming Controlled Release Society 2024 Annual Meeting and Expo being held in Bologna, Italy from July 8-12, 2024.
- CNW Group
Eupraxia Pharmaceuticals' CEO Dr. James Helliwell to Participate in Webinar Event, "Exploring the Rapid Rise of Osteoarthritis" on July 9, 2024
Eupraxia Pharmaceuticals Inc. ("Eupraxia" or the "Company") (TSX: EPRX) (NASDAQ: EPRX), a clinical-stage biotechnology company leveraging its proprietary DiffuSphere™ technology to optimize drug delivery for applications with significant unmet need, today announced that Eupraxia's CEO, Dr. James A. Helliwell, will present at a Tribe Public Webinar Presentation and Q&A Event titled, "Exploring The Rapid Rise of Osteoarthritis".
- PR Newswire
Eupraxia Pharmaceuticals Announces Voting Results from Annual General and Special Meeting of Shareholders
Eupraxia Pharmaceuticals Inc. ("Eupraxia" or the "Company") (TSX: EPRX) (NASDAQ: EPRX), a clinical-stage biotechnology company leveraging its proprietary DiffuSphere™ technology to optimize drug delivery for applications with significant unmet need, is pleased to announce the results from its Annual General and Special Meeting of Shareholders (the "Meeting") held on June 6, 2024.
